<DOC>
	<DOCNO>NCT02984501</DOCNO>
	<brief_summary>There clear consensus regard optimal treatment locally advance pancreatic disease . There potential role neoadjuvant therapy treat micrometastatic disease chemotherapy , well treatment local disease radiotherapy . The investigator evaluate safety efficacy induction chemotherapy oxaliplatin gemcitabine follow high weekly dose gemcitabine concurrent radiation therapy patient borderline resectable unresectable locally advanced pancreatic cancer</brief_summary>
	<brief_title>Study Induction Chemotherapy Followed Radiochemotherapy Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Continued optimization multimodality therapy accurate patient selection remain crucial point appropriate treatment patient pancreatic cancer . In patient accurate pre-treatment staging perform , include : physical examination , complete blood test tumor marker , endoscopic ultrasonography ( EUS ) fine needle aspiration biopsy , multilayer CT scan , PET-CT ( positron emission compute tomography ) 18F-2-fluoro-2-deoxy-D-glucose ( FDG ) laparoscopy peritoneal washing . Jaundiced patient treatment underwent endoscopic biliary stenting . Patients evidence metastatic disease exclude , thus small number patient consequently enrol neoadjuvant approach . The induction phase treatment plan design administer gemcitabine 1000 mg/mq oxaliplatin 100 mg/mq every 14 day four dos . In combined phase treatment patient underwent simulation use Siemens 16-CT simulator ( Siemens Medical System ) . Radiotherapy target volume establish CT scan PET-CT scan . Four week completion radiochemotherapy , restaging , consist clinical examination , laboratory test , tumor marker , CT scan PET-CT scan , perform . Tumor response define accordance World Health Organization ( WHO ) definition CT scan PET-CT scan . Surgery consider patient whose tumor technically resectable . After resection , patient evaluate every three month mean standard surveillance protocol include history physical examination , cross-sectional imaging measurement serum marker , interval extend six month two year</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>proven cytological histological diagnosis pancreatic ductal adenocarcinoma ; borderline resectable unresectable pancreatic tumour ; age 18 75 year ; previous radiochemotherapy abdomen ; 0I ECOG ( Eastern Cooperative Oncology Group ) performance status ; adequate cardiac , liver kidney function good bone marrow reserve . resectable metastatic disease ; previous concomitant malignant disease ; one follow clinical condition : infection , pregnancy breastfeeding , liver failure , kidney failure , Pa O2 &lt; 65 mmHg , Pa CO2 &gt; 40 mmHg , mental disability .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>radiochemotherapy</keyword>
	<keyword>neoadjuvant therapy</keyword>
</DOC>